Empagliflozin

CAS 864070-44-0 42 API suppliersSmall Molecule

Overview

Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the treatment of type 2 diabetes. It helps lower blood sugar levels by preventing glucose reabsorption in the kidneys, promoting its excretion.

API suppliers (42)

Suppliers of Empagliflozin evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.

Where these suppliers are
India25China6Netherlands1USA1Pakistan1Spain1

Country recorded for 35 of 42 suppliers.

18 of 42 hold a GMP certificate on record in the EU or UK registers

Showing 25 of 42 suppliers — see the full list in the app.

Patent & exclusivity (US)

Per the FDA Orange Book (2 approved US products), the latest listed US patent on Empagliflozin expires 11 Dec 2034 and exclusivity 20 Dec 2026. Generic API sourcing typically opens up once these lapse.

Therapeutic areas

DiabetesCardiovascularEndocrinology
Verified Supplier Partner

Do you supply Empagliflozin? Get in front of buyers actively sourcing it.

We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.

No cost to enquire · we only reach out with a fit.

Ready to Accelerate Your
Discovery Workflow?

Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.